US-based regenerative technologies company StimLabs has announced the commercialisation of its new placental membrane-based product, dubbed Enverse.
Enverse is a translucent dehydrated complete human placental membrane (dCHPM) allograft product, designed to serve as a covering over acute and chronic wounds.
The company claimed that its new dCHPM allograft has been processed using its patented Clearify method to retain the intermediate layer of the placental membrane.
The native placental membrane is a complex biological tissue that contains various extracellular matrix components, distributed across three native layers.
In addition, the allograft is stabilised using a patented oven-dehydration process, which enables in a compact, translucent format, said StimLabs.
With the roll-out of Enverse, the company expands its product portfolio to address the broad spectrum of requirements in healthcare facilities.
StimLabs said that its new product, which is now available for both physician-owned and hospital-owned facilities, will help simplify patient care.
Enverse is said to facilitate increased application site visibility and enable superior handling.
Established in 2015, Stimlabs has developed and launched a suite of placental-derived products, a portfolio of other products and clinical applications.
In March this year, the company announced the rebranding of its hospital-based dCHPM portfolio to Vialize.
In January 2020, StimLabs unveiled its new dehydrated umbilical cord-derived allograft product Corplex intended to be used as a wound covering for acute and chronic wounds.
